GB1435916A - Pharmaceutical weight-reducing compositions - Google Patents

Pharmaceutical weight-reducing compositions

Info

Publication number
GB1435916A
GB1435916A GB2210572A GB2210572A GB1435916A GB 1435916 A GB1435916 A GB 1435916A GB 2210572 A GB2210572 A GB 2210572A GB 2210572 A GB2210572 A GB 2210572A GB 1435916 A GB1435916 A GB 1435916A
Authority
GB
United Kingdom
Prior art keywords
alkyl
compositions
methyl
adenine
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB2210572A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Priority to GB2210572A priority Critical patent/GB1435916A/en
Priority to IL42145A priority patent/IL42145A0/xx
Priority to BE130788A priority patent/BE799141A/xx
Priority to FR7316658A priority patent/FR2183979A1/fr
Priority to NL7306507A priority patent/NL7306507A/xx
Priority to AU55619/73A priority patent/AU5561973A/en
Priority to DE2323906A priority patent/DE2323906A1/de
Priority to JP48053045A priority patent/JPS4947519A/ja
Publication of GB1435916A publication Critical patent/GB1435916A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
GB2210572A 1972-05-11 1972-05-11 Pharmaceutical weight-reducing compositions Expired GB1435916A (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GB2210572A GB1435916A (en) 1972-05-11 1972-05-11 Pharmaceutical weight-reducing compositions
IL42145A IL42145A0 (en) 1972-05-11 1973-04-30 Reduction of body weight in mammals and compositions therefor comprising a mixture of carnitine and one or more lipolytic factor
BE130788A BE799141A (fr) 1972-05-11 1973-05-04 Composition pharmaceutique utilisable pour le traitement de l'obesite
FR7316658A FR2183979A1 (enExample) 1972-05-11 1973-05-09
NL7306507A NL7306507A (enExample) 1972-05-11 1973-05-10
AU55619/73A AU5561973A (en) 1972-05-11 1973-05-11 Pharmaceutical composition incorporating carnitine pharmaceutical composition incorporating carnitine
DE2323906A DE2323906A1 (de) 1972-05-11 1973-05-11 Pharmazeutisches praeparat gegen fettleibigkeit
JP48053045A JPS4947519A (enExample) 1972-05-11 1973-05-11

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2210572A GB1435916A (en) 1972-05-11 1972-05-11 Pharmaceutical weight-reducing compositions

Publications (1)

Publication Number Publication Date
GB1435916A true GB1435916A (en) 1976-05-19

Family

ID=10173983

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2210572A Expired GB1435916A (en) 1972-05-11 1972-05-11 Pharmaceutical weight-reducing compositions

Country Status (8)

Country Link
JP (1) JPS4947519A (enExample)
AU (1) AU5561973A (enExample)
BE (1) BE799141A (enExample)
DE (1) DE2323906A1 (enExample)
FR (1) FR2183979A1 (enExample)
GB (1) GB1435916A (enExample)
IL (1) IL42145A0 (enExample)
NL (1) NL7306507A (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903558A1 (de) * 1978-02-03 1979-08-09 Sigma Tau Ind Farmaceuti Therapeutisches verfahren zur behandlung von hyperlipoproteinaemie und hyperlipidaemie sowie arzneimittel zu seiner durchfuehrung
US4434160A (en) 1980-07-11 1984-02-28 Leopold & Co. Chem. Pharm. Fabrik Gesellschaft M.B.H. Nutrient solution for complete parenteral feeding and for increased energy production
GB2132085A (en) * 1982-10-29 1984-07-04 Sigma Tau Ind Farmaceuti Pharmaceutical composition containing l-carnitine
US5734052A (en) * 1993-05-06 1998-03-31 Merrell Pharmaceuticals Inc. 8-substituted xanthines as selective adenosine receptor agents
AT413943B (de) * 2004-03-05 2006-07-15 Lohninger Alfred Dr L-carnitin enthaltende, oral verabreichbare zusammensetzung
GB2457710A (en) * 2008-02-25 2009-08-26 Andrew Nicolaou Thyroxine and its use in weight loss and obesity treatment

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7810947L (sv) * 1978-10-20 1980-04-21 Draco Ab 3-alkylxanthines
SE7810946L (sv) * 1978-10-20 1980-04-21 Draco Ab Metod att behandla kronisk obstruktiv luftvegssjukdom
FR2619007B1 (fr) * 1987-08-07 1990-09-28 Dermatologiques Et Preparations cosmetiques a action lipolytique
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903558A1 (de) * 1978-02-03 1979-08-09 Sigma Tau Ind Farmaceuti Therapeutisches verfahren zur behandlung von hyperlipoproteinaemie und hyperlipidaemie sowie arzneimittel zu seiner durchfuehrung
US4434160A (en) 1980-07-11 1984-02-28 Leopold & Co. Chem. Pharm. Fabrik Gesellschaft M.B.H. Nutrient solution for complete parenteral feeding and for increased energy production
GB2132085A (en) * 1982-10-29 1984-07-04 Sigma Tau Ind Farmaceuti Pharmaceutical composition containing l-carnitine
US5734052A (en) * 1993-05-06 1998-03-31 Merrell Pharmaceuticals Inc. 8-substituted xanthines as selective adenosine receptor agents
AT413943B (de) * 2004-03-05 2006-07-15 Lohninger Alfred Dr L-carnitin enthaltende, oral verabreichbare zusammensetzung
GB2457710A (en) * 2008-02-25 2009-08-26 Andrew Nicolaou Thyroxine and its use in weight loss and obesity treatment

Also Published As

Publication number Publication date
AU5561973A (en) 1974-11-14
DE2323906A1 (de) 1973-11-22
FR2183979A1 (enExample) 1973-12-21
IL42145A0 (en) 1973-06-29
JPS4947519A (enExample) 1974-05-08
BE799141A (fr) 1973-11-05
NL7306507A (enExample) 1973-11-13

Similar Documents

Publication Publication Date Title
IL103301A (en) Pyrimidine nucleoside derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
ATE4903T1 (de) 1-, 6- und 2-substituierte 1-carba-2-penem-3carbons[ure, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
JPS568352A (en) Aminoalkylvenzene derivative
IE39898L (en) Xanthine derivatives
ES481729A1 (es) Procedimiento para la preparacion de derivados de 1,2-dihi- droquinolein-2-onas.
AU2736088A (en) Pharmaceutical compositions comprising benzylidene- and cinnamylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation
GB1435916A (en) Pharmaceutical weight-reducing compositions
JPS56103168A (en) Thiazole derivative, its preparation, and antihistaminic agent containing the same
EP0186023A3 (en) Biliary acid derivatives, process for their preparation and pharmaceutical compositions containing them
ES2013379A6 (es) Procedimiento para preparar 6-sulfenamido-6, sulfinamido- y 6-sulfonamido-purinas, nucleosidos de purinas y nucleotidos de purinas antitumorales.
JPS5424895A (en) Pyranochromone derivatives and remedies for allergic disorder
ES486049A1 (es) Procedimiento para la obtencion de derivados aminopropanoli-cos de la 6-hidroxi-2,3,4,5-tetrahidro-1h-1-benzazepin-2-ona
JPS5297934A (en) N#-arylsulfonyl-l-argininamides and their salts acceptable as medicine s
JPS5735576A (en) 4,1-benzoxazepin-3-acetic derivative and its production
GB1468079A (en) Ethanolamine derivatives
ES8702360A1 (es) Procedimiento para preparar derivados de quinoleina
ES355312A1 (es) Procedimiento de fabricacion de nuevos derivados de pirimi-dina.
ES386465A1 (es) Procedimiento para la preparacion de derivados de neriifo- lina.
JPS523099A (en) Pyrido 2,3-c acridine-1-hydroxy-2-carboxylic preparing the same
JPS57140783A (en) 1-benzyl-4-(4-(2-pyrimidinylamino)benzyl)-2, 3-dioxopiperazine derivative and its salt, their preparation, and carcinostatic agent containing the same
JPS55104266A (en) Novel pyridone derivative
JPS525796A (en) Preparation of tetrahydropyrido pyrimidinone derivatives
JPS5639074A (en) Pyrimidine derivative
JPS5242888A (en) Preparation of quinazoline derivatives
JPS554334A (en) Pyranopyrazole derivative

Legal Events

Date Code Title Description
CSNS Application of which complete specification have been accepted and published, but patent is not sealed